Thrivent Financial for Lutherans
CCXI

Thrivent Financial for Lutherans’s ChemoCentryx, Inc. CCXI Stock Holding History

Thrivent Financial for Lutherans’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-66,747
Closed -$625K – 2438
2017
Q2 		$625K Sell
66,747
-50,290
-43% -$369K ﹤0.01% 1388
2017
Q1 		$852K Buy
+117,037
New +$843K ﹤0.01% 1268

Other funds holding CCXI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans's CCXI Position: Q3 2017 in Review

Thrivent Financial for Lutherans sold out of ChemoCentryx, Inc. (CCXI) in Q3 2017, closing a stake of 66,747 shares — an estimated $625K sold.

Thrivent Financial for Lutherans first reported a position in CCXI in Q1 2017 and held it in 2 quarters. The position peaked at $852K in Q1 2017. 86 funds tracked by Wall St. Rank hold CCXI as of Q3 2017.

  • Thrivent Financial for Lutherans reported no remaining ChemoCentryx, Inc. position as of Q3 2017 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 66,747 ChemoCentryx, Inc. shares in Q3 2017, an estimated $625K.
  • Thrivent Financial for Lutherans first reported a position in ChemoCentryx, Inc. in Q1 2017 and held it in 2 quarters.
  • Thrivent Financial for Lutherans's ChemoCentryx, Inc. position peaked at $852K in Q1 2017.
  • 86 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2017.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2017, filed 14 Nov 2017.